Literature DB >> 12482123

Correlation of sera TNF-alpha with percentage of bone marrow plasma cells, LDH, beta2-microglobulin, and clinical stage in multiple myeloma.

Vladimir Jurisić1, Milica Colović.   

Abstract

Tumor necrosis factor-alpha (TNF-alpha) is important for function, differentiation, and transformation of B-lymphocytes in multiple myeloma (MM) but can also induce apoptosis of myeloma cells. Based on this opposite effect, it is very crucial to analyze the correlation of the serum level of TNF-alpha with clinical parameters of the patients. In this article, we analyzed 18 MM patients, 48% male and 52% female, with a mean age of 52 yr (range: 35-81 yr), clinical stage I in 21.4%, stage II in 26.4%, and stage III in 52.2% of patients. Patients with advanced clinical stage, presence of osteolysis, and elevated lactate dehydrogenase (LDH) had a significant difference (Mann-Whitney U-test, p < 0.05) in the serum level of TNF-alpha in comparison with those in the early stage, without osteolysis, and normal LDH. The correlation of individual values of TNF-alpha with the percentage of plasma cells in the bone marrow, LDH, beta2-microglobulin, fibrinogen, and sedimentation rate was significant (p < 0.05). However, we have not found a significant correlation between TNF-alpha and concentration of hemoglobin, the number of white blood cells or platelets (p > 0.05). We concluded that our data indicate determination of TNF-alpha as a good parameter for estimation of tumor mass presence, among individual patients with MM, and may by used for monitoring during application of different therapy protocols.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12482123     DOI: 10.1385/MO:19:3:133

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  18 in total

1.  Different alterations in lactate dehydrogenase activity and profile of peripheral blood mononuclear cells in Hodgkin's and non-Hodgkin's lymphomas.

Authors:  V Jurisić; G Konjević; B Banićević; B Duricić; I Spuzić
Journal:  Eur J Haematol       Date:  2000-04       Impact factor: 2.997

2.  Interleukin 6, tumour necrosis factor alpha and lymphotoxin alpha polymorphisms in monoclonal gammopathy of uncertain significance and multiple myeloma.

Authors:  A M Dring; F E Davies; S J Rollinson; P L Roddam; A C Rawstron; J A Child; A S Jack; G J Morgan
Journal:  Br J Haematol       Date:  2001-01       Impact factor: 6.998

3.  Increased T cell cytotoxicity by Betathine-induced upregulation of TNFalpha.

Authors:  T M Dunn; S Wormsley; F E Taub; C H Pontzer
Journal:  Int J Immunopharmacol       Date:  2000-03

4.  Tumor necrosis factor-alpha and interferon-gamma in serum of multiple myeloma patients.

Authors:  P Pisa; L Stenke; P Bernell; M Hansson; R Hast
Journal:  Anticancer Res       Date:  1990 May-Jun       Impact factor: 2.480

5.  TNF receptor family member BCMA (B cell maturation) associates with TNF receptor-associated factor (TRAF) 1, TRAF2, and TRAF3 and activates NF-kappa B, elk-1, c-Jun N-terminal kinase, and p38 mitogen-activated protein kinase.

Authors:  A Hatzoglou; J Roussel; M F Bourgeade; E Rogier; C Madry; J Inoue; O Devergne; A Tsapis
Journal:  J Immunol       Date:  2000-08-01       Impact factor: 5.422

6.  A quick and simple method for the quantitation of lactate dehydrogenase release in measurements of cellular cytotoxicity and tumor necrosis factor (TNF) activity.

Authors:  T Decker; M L Lohmann-Matthes
Journal:  J Immunol Methods       Date:  1988-11-25       Impact factor: 2.303

7.  Apoptosis, proliferation and NF-kappaB activation induced by agonistic Fas antibodies in the human myeloma cell line OH-2: amplification of Fas-mediated apoptosis by tumor necrosis factor.

Authors:  M Børset; H Hjorth-Hansen; A C Johnsen; C Seidel; A Waage; T Espevik; A Sundan
Journal:  Eur J Haematol       Date:  1999-11       Impact factor: 2.997

8.  [Level of interleukin-6 (IL-6), soluble interleukin-6 receptors (sIL-6R) and tumor necrosis factor alpha (TNF-alpha) in untreated and progressing multiple myeloma].

Authors:  L Usnarska-Zubkiewicz
Journal:  Pol Arch Med Wewn       Date:  1998-01

9.  Measurement of serum cytokine levels in patients with myelodysplastic syndromes.

Authors:  G E Verhoef; P De Schouwer; J L Ceuppens; J Van Damme; W Goossens; M A Boogaerts
Journal:  Leukemia       Date:  1992-12       Impact factor: 11.528

10.  TNF and IL-6 are potent growth factors for OH-2, a novel human myeloma cell line.

Authors:  M Börset; A Waage; O L Brekke; E Helseth
Journal:  Eur J Haematol       Date:  1994-07       Impact factor: 2.997

View more
  21 in total

1.  Bone density loss in Crohn's disease: role of TNF and potential for prevention by bupropion.

Authors:  R E Kast; E L Altschuler
Journal:  Gut       Date:  2004-07       Impact factor: 23.059

2.  Analysis of CD23 antigen expression in B-chronic lymphocytic leukaemia and its correlation with clinical parameters.

Authors:  Vladimir Jurisic; Natasa Colovic; Nada Kraguljac; Henry Dushan Atkinson; Milica Colovic
Journal:  Med Oncol       Date:  2008-01-09       Impact factor: 3.064

Review 3.  TNF-α, a good or bad factor in hematological diseases?

Authors:  Tian Tian; Min Wang; Daoxin Ma
Journal:  Stem Cell Investig       Date:  2014-06-01

4.  Clinical stage-depending decrease of NK cell activity in multiple myeloma patients.

Authors:  Vladimir Jurisic; Tatjana Srdic; Gordana Konjevic; Olivera Markovic; Milica Colovic
Journal:  Med Oncol       Date:  2007       Impact factor: 3.064

5.  The comparison of spontaneous LDH release activity from cultured PBMC with sera LDH activity in non-Hodgkin's lymphoma patients.

Authors:  V Jurisić; G Konjević; R Jancić-Nedeljkov; M Sretenović; B Banicević; M Colović; I Spuzić
Journal:  Med Oncol       Date:  2004       Impact factor: 3.064

6.  Longitudinal analysis of patient-reported symptoms post-autologous stem cell transplant and their relationship to inflammation in patients with multiple myeloma.

Authors:  Xin Shelley Wang; Qiuling Shi; Loretta A Williams; Nina D Shah; Tito R Mendoza; Evan N Cohen; James M Reuben; Charles S Cleeland; Robert Z Orlowski
Journal:  Leuk Lymphoma       Date:  2014-11-20

7.  Minocycline for symptom reduction in patients with multiple myeloma during maintenance therapy: a phase II placebo-controlled randomized trial.

Authors:  Xin Shelley Wang; Qiuling Shi; Tito R Mendoza; Araceli Garcia-Gonzalez; Ting-Yu Chen; Mona Kamal; Tsun Hsuan Chen; Cobi Heijnen; Robert Z Orlowski; Charles S Cleeland
Journal:  Support Care Cancer       Date:  2021-04-01       Impact factor: 3.603

8.  TNFR1 and TNFR2 regulate the extrinsic apoptotic pathway in myeloma cells by multiple mechanisms.

Authors:  H Rauert; T Stühmer; R Bargou; H Wajant; D Siegmund
Journal:  Cell Death Dis       Date:  2011-08-18       Impact factor: 8.469

Review 9.  Inflammatory and Anti-Inflammatory Equilibrium, Proliferative and Antiproliferative Balance: The Role of Cytokines in Multiple Myeloma.

Authors:  Caterina Musolino; Alessandro Allegra; Vanessa Innao; Andrea Gaetano Allegra; Giovanni Pioggia; Sebastiano Gangemi
Journal:  Mediators Inflamm       Date:  2017-09-26       Impact factor: 4.711

Review 10.  Notch signaling deregulation in multiple myeloma: A rational molecular target.

Authors:  Michela Colombo; Serena Galletti; Silvia Garavelli; Natalia Platonova; Alessandro Paoli; Andrea Basile; Elisa Taiana; Antonino Neri; Raffaella Chiaramonte
Journal:  Oncotarget       Date:  2015-09-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.